|
1
|
Gandomani HS, Yousefi SM, Aghajani M,
Mohammadian-Hafshejani A, Tarazoj AA, Pouyesh V and Salehiniya H:
Colorectal cancer in the world: Incidence, mortality and risk
factors. Biomed Res Therapy. 4:102017. View Article : Google Scholar
|
|
2
|
Haggar FA and Boushey RP: Colorectal
cancer epidemiology: Incidence, mortality, survival, and risk
factors. Clin Colon Rectal Surg. 22:191–197. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Mishra J, Dromund J, Quazi SH, Karanki SS,
Shaw JJ, Chen B and Kumar N: Prospective of colon cancer treatments
and scope for combinatorial approach to enhanced cancer cell
apoptosis. Crit Rev Oncol Hematol. 86:232–250. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Wáng YX, De Baere T, Idée JM and Ballet S:
Transcatheter embolization therapy in liver cancer: An update of
clinical evidences. Chin J Cancer Res. 27:96–121. 2015.PubMed/NCBI
|
|
5
|
Blakely T, Collinson L, Kvizhinadze G,
Nair N, Foster R, Dennett E and Sarfati D: Cancer care coordinators
in stage III colon cancer: A cost-utility analysis. BMC Health Serv
Res. 15:3062015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Keating NL, Landrum MB, Lamont EB, Bozeman
SR, Krasnow SH, Shulman LN, Brown JR, Earle CC, Oh WK, Rabin M and
McNeil BJ: Quality of care for older patients with cancer in the
Veterans health administration versus the private sector: A cohort
study. Ann Intern Med. 154:727–736. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Lam TJ, Meurs-Szojda MM, Gundlach L,
Belien JA, Meijer GA, Mulder CJ and Felt-Bersma RJ: There is no
increased risk for colorectal cancer and adenomas in patients with
diverticulitis: A retrospective longitudinal study. Colorectal Dis.
12:1122–1126. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Suraj R, Radhamani S, Meehan-Andrews T and
Bradley C: Role of a novel benzoxazine derivative in the
chemosensitization of colon cancer. Apoptosis. 22:988–1000. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Kadioglu O, Law BYK, Mok SWF, Xu SW,
Efferth T and Wong VKW: Mode of action analyses of neferine, a
bisbenzylisoquinoline alkaloid of lotus (Nelumbo nucifera) against
multidrug-resistant tumor cells. Front Pharmacol. 8:2382017.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kang XJ, Wang HY, Peng HG, Chen BF, Zhang
WY, Wu AH, Xu Q and Huang YZ: Codelivery of dihydroartemisinin and
doxorubicin in mannosylated liposomes for drug-resistant colon
cancer therapy. Acta Pharmacol Sin. 38:885–896. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Xu J, Zhang S, Wang R, Wu X, Zeng L and Fu
Z: Knockdown of PRDX2 sensitizes colon cancer cells to 5-FU by
suppressing the PI3K/AKT signaling pathway. Biosci Rep.
37:BSR201604472017. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Nedaeinia R, Avan A, Ahmadian M, Nia SN,
Ranjbar M, Sharifi M, Goli M, Piroozmand A, Nourmohammadi E, Manian
M, et al: Current status and perspectives regarding LNA-Anti-miR
oligonucleotides and microRNA miR-21 inhibitors as a potential
therapeutic option in treatment of colorectal cancer. J Cell
Biochem. 118:4129–4140. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Sambi M, Haq S, Samuel V, Qorri B, Haxho
F, Hill K, Harless W and Szewczuk MR: Alternative therapies for
metastatic breast cancer: Multimodal approach targeting tumor cell
heterogeneity. Breast Cancer (Dove Med Press). 9:85–93.
2017.PubMed/NCBI
|
|
14
|
Schoumacher M and Burbridge M: Key roles
of AXL and MER receptor tyrosine kinases in resistance to multiple
anticancer therapies. Curr Oncol Rep. 19:192017. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zheng D, Wu W, Dong N, Jiang X, Xu J, Zhan
X, Zhang Z and Hu Z: Mxd1 mediates hypoxia-induced cisplatin
resistance in osteosarcoma cells by repression of the PTEN tumor
suppressor gene. Mol Carcinog. 56:2234–2244. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
El Ouar I, Braicu C, Naimi D, Irimie A and
Berindan-Neagoe I: Effect of Helix aspersa extract on TNFα, NF-κB
and some tumor suppressor genes in breast cancer cell line Hs578T.
Pharmacogn Mag. 13:281–285. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Mantamadiotis T: Towards targeting
PI3K-dependent regulation of gene expression in brain cancer.
Cancers (Basel). 9:E602017. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Ban HS, Kim BK, Kim HM, Harmalkar D, Nam
M, Park SK, Lee K, Park JT, Kim I, et al: The novel
hypoxia-inducible factor-1α inhibitor IDF-11774 regulates cancer
metabolism, thereby suppressing tumor growth. Cell Death Dis.
8:e28432017. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Tesio M, Trinquand A, Ballerini P,
Hypolite G, Lhermitte L, Petit A, Ifrah N, Baruchel A, Dombret H,
Macintyre E and Asnafi V: Age-related clinical and biological
features of PTEN abnormalities in T-cell acute lymphoblastic
leukaemia. Leukemia. 31:2594–2600. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Li Z, Dong X, Wang Z, Liu W, Deng N, Ding
Y, Tang L, Hla T, Zeng R, Li L and Wu D: Regulation of PTEN by Rho
small GTPases. Nat Cell Biol. 7:399–404. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Solari F, Bourbon-Piffaut A, Masse I,
Payrastre B, Chan AM and Billaud M: The human tumour suppressor
PTEN regulates longevity and dauer formation in Caenorhabditis
elegans. Oncogene. 24:20–27. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Bar N and Dikstein R: miR-22 forms a
regulatory loop in PTEN/AKT pathway and modulates signaling
kinetics. PLoS One. 5:e108592010. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Chalhoub N and Baker SJ: PTEN and the
PI3-Kinase pathway in cancer. Annu Rev Pathol. 4:127–150. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Keniry M and Parsons R: The role of PTEN
signaling perturbations in cancer and in targeted therapy.
Oncogene. 27:5477–5485. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Korkaya H, Kim GI, Davis A, Malik F, Henry
NL, Ithimakin S, Quraishi AA, Tawakkol N, D'Angelo R, Paulson AK,
et al: Activation of an IL-6 inflammatory loop mediates trastuzumab
resistance in HER2+ breast cancers by expanding the cancer stem
cell population. Mol Cell. 47:570–584. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Zarogoulidis P, Yarmus L, Darwiche K,
Walter R, Huang H, Li Z, Zaric B, Tsakiridis K and Zarogoulidis K:
Interleukin-6 cytokine: A multifunctional glycoprotein for cancer.
Immunome Res. 9:165352013. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
El-Badawy A, Ghoneim MA, Gabr MM, Salah
RA, Mohamed IK, Amer M and El-Badri N: Cancer cell-soluble factors
reprogram mesenchymal stromal cells to slow cycling, chemoresistant
cells with a more stem-like state. Stem Cell Res Ther. 8:2542017.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Hu T, Li Z, Gao CY and Cho CH: Mechanisms
of drug resistance in colon cancer and its therapeutic strategies.
World J Gastroenterol. 22:6876–6889. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Hammond WA, Swaika A and Mody K:
Pharmacologic resistance in colorectal cancer: A review. Ther Adv
Med Oncol. 8:57–84. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Pu H, Zheng Q, Li H, Wu M, An J, Gui X, Li
T and Lu D: CUDR promotes liver cancer stem cell growth through
upregulating TERT and C-Myc. Oncotarget. 6:40775–40798. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Phadngam S, Castiglioni A, Ferraresi A,
Morani F, Follo C and Isidoro C: PTEN dephosphorylates AKT to
prevent the expression of GLUT1 on plasmamembrane and to limit
glucose consumption in cancer cells. Oncotarget. 7:84999–85020.
2016. View Article : Google Scholar : PubMed/NCBI
|
